3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
699
Breast Neoplasms
630
Neoplasms
582
Leukemia, Myeloid, Acute
481
Colorectal Neoplasms
456
Multiple Myeloma
444
Melanoma
426
Prostatic Neoplasms
383
Neoplasm Metastasis
373
Pancreatic Neoplasms
363
Recurrence
350
Lymphoma
340
Ovarian Neoplasms
325
Lung Neoplasms
297
Lymphoma, Non-Hodgkin
295
Leukemia
287
Glioblastoma
275
Precursor Cell Lymphoblastic Leukemia-Lymphoma
249
Stomach Neoplasms
246
Leukemia, Lymphocytic, Chronic, B-Cell
235
Carcinoma, Hepatocellular
231
Squamous Cell Carcinoma of Head and Neck
220
Lymphoma, Large B-Cell, Diffuse
217
Myelodysplastic Syndromes
212
Carcinoma, Renal Cell
210
Lymphoma, Follicular
183
Head and Neck Neoplasms
172
Brain Neoplasms
169
Lymphoma, Mantle-Cell
167
Triple Negative Breast Neoplasms
166
Interventions
palbociclib
1
aumolertinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Interventional
×
EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor
×
Clear all
NCT06947811
2025-06-04
APEAK
Sun Yat-sen University
Phase 1/2
Recruiting
71 enrolled